Hims & Hers' Guidance Reset Sparks Sell-Off as Growth Expectations Crumble

The numbers themselves were a clean beat. For the fourth quarter of 2025, Hims & Hers Health posted revenue of $617.8 million, meeting the Wall Street consensus. More striking was the profit. The company's GAAP profit of $0.08 per share was 92.5% above analysts' consensus estimates. On the surface, this is a classic "beat and raise" setup. Yet the stock fell about 6.3% after the report. The market's reaction tells the real story: the whisper number for the quarter was likely higher than the official consensus, and the beat wasn't enough to offset fresh concerns about the path ahead.

The expectation gap was clear. While revenue hit the printed estimate, the pre-earnings momentum and the sheer magnitude of the EPS beat suggest investors were braced for even stronger results. The stock's decline points to a classic "sell the news" dynamic. The market had already priced in a solid quarter, so a clean beat against a soft whisper number failed to move the needle. The real focus, as the price action shows, was always on what management would say next.

This sets the stage for the deeper tension. A strong past quarter is a good thing, but it's not a substitute for a compelling future. The guidance reset that followed would become the new focal point, and the market's disappointment with the Q4 print was just the opening act.

The Guidance Reset: Where the Expectation Gap Widened

The Q4 beat was just the warm-up. The real sell-off came with the forward view. Management's guidance for the coming year reset the bar lower than the market had already priced in, widening the expectation gap into a chasm.

The numbers tell the story. For the first quarter of 2026, the company guided to revenue of $612.5 million at the midpoint. That figure landed 5.6% below the consensus estimate of $649 million. More broadly, full-year 2026 EBITDA guidance of $337.5 million at the midpoint fell short of the $356.1 million consensus. This wasn't a minor miss; it was a clear guidance reset that undercut the growth trajectory investors were banking on.

Viewed through the lens of expectation arbitrage, this is a classic "beat and lower" scenario. The market had already bought the rumor of continued high growth, and the print confirmed a slowdown. The whisper number for next year's earnings was likely higher than the official consensus, and management's guidance failed to meet even that soft baseline. The stock's decline after the report reflects this reset in forward expectations.

The guidance reset was compounded by rising execution and regulatory risks. An SEC probe into GLP-1 compounding introduces uncertainty into a key part of the business, adding a layer of friction that wasn't fully priced in. This combination-softer growth numbers paired with increased regulatory overhang-shifted the narrative from "can they grow?" to "what could go wrong?" The market's reaction was a vote for caution, punishing the stock for a future that now looks less certain.

Valuation & Underlying Demand: What's Priced In?

The steep sell-off has reset the valuation, but the underlying business shows a mixed picture of resilience and emerging strain. The stock is down about 70% over the past year, trading at a forward P/E of roughly 14x. That's a steep discount from its recent highs, suggesting the market has priced in a significant slowdown. The question is whether this reflects a temporary reset or a structural change in growth.

On the demand front, the subscriber base remains a bright spot. The company ended the quarter with 2.51 million customers, up 13% year-over-year. This growth, coupled with a 31% increase in customers using at least one personalized subscription, shows that core demand for its platform is still expanding. The market had priced in hyper-growth, but this resilience suggests the fundamental user base isn't crumbling.

The cash flow picture, however, introduces a critical new risk. For the first time in recent quarters, free cash flow turned negative, with a burn of -$2.57 million in Q4, down sharply from $59.5 million a year ago. This shift from a strong cash generator to a cash consumer raises immediate concerns about capital efficiency and the sustainability of its growth model. It's a tangible sign that the path to profitability is getting steeper.

So, what's priced in? The valuation discount likely reflects the guidance reset and the GLP-1 overhang. The subscriber growth suggests the core business is still working, but the cash burn adds a layer of execution risk that wasn't fully priced in. The expectation gap has widened from just revenue growth to include cash generation. For now, the sell-off appears to be a rational reassessment of risk, not a panic over a broken model. The stock's deep discount offers a potential entry point, but only for investors willing to bet that the cash flow issues are temporary and that the company can navigate its regulatory hurdles to return to its high-growth trajectory.

Catalysts & Risks: Closing the Expectation Gap

The current valuation offers a potential entry point, but the path to closing the expectation gap hinges on a few key catalysts and risks. The next major event is the upcoming earnings call on May 4, 2026. This will be the first real test of whether management can rebuild confidence with a stronger forward outlook. After the guidance reset that undercut the market's soft baseline, any meaningful improvement in the trajectory for 2026 will be scrutinized for signs of a genuine recovery. A failure to provide a clearer, more optimistic path could cement the stock's downtrend.

Analyst sentiment remains a significant overhang. Reactions to the last report were negative, with BTIG downgrading the stock from Buy to Neutral and Citigroup cutting its price target to $13.25. The average analyst target still sits around $32, but the consensus rating has shifted to "Hold," reflecting a loss of conviction. These moves signal that the market's initial optimism has been replaced by caution, and the stock's deep discount now reflects this lowered bar.

On the growth side, the company's international expansion via an agreement to acquire Eucalyptus for up to $1.15 billion is a potential long-term driver. If executed well, this could unlock new revenue streams and diversify the business. Yet, it also introduces integration risk and requires significant capital, a factor that may be at odds with the company's recent cash burn. For now, it's a high-stakes bet on the future that the market is not yet pricing in as a near-term catalyst.

The bottom line is that the expectation gap is wide, and closing it will require more than just a beat. The next earnings call is the immediate catalyst to watch. If management can provide a credible plan to navigate the GLP-1 regulatory risk, improve cash flow, and deliver on the international promise, the stock could find a floor. Until then, the negative analyst actions and the company's own guidance reset suggest the market is pricing in a period of continued uncertainty.